Jasper Therapeutics Stock Price, News & Analysis

Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company in the biological product manufacturing sector that is focused on developing briquilimab as a therapeutic for chronic mast cell diseases. According to company disclosures, Jasper is advancing briquilimab as a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT (CD117). By inhibiting signaling through this receptor, briquilimab disrupts a critical survival signal for mast cells, leading to their depletion via apoptosis and removing an underlying source of inflammatory responses in mast cell driven diseases such as chronic urticaria and asthma.

Jasper describes itself as a clinical-stage company, meaning its lead program is being evaluated in human studies rather than being commercially marketed. The company is conducting clinical studies of briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. Across its public communications, Jasper reports that briquilimab has demonstrated an efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma in the studies conducted to date.

Focus on mast cell driven diseases

The company states that its development strategy centers on mast cell driven diseases, where mast cells are believed to play a central role in driving inflammation and symptoms. In CSU and CIndU, Jasper’s clinical programs are designed around chronic urticaria indications, while in asthma the company has evaluated briquilimab in allergic asthma patients. By targeting KIT and depleting mast cells, briquilimab is intended to address the inflammatory cascade underlying these conditions as described in Jasper’s press releases.

Jasper has reported data from multiple clinical studies, including the BEACON Phase 1b/2a study in adult participants with CSU, an open-label extension study enrolling CSU and CIndU patients from earlier trials, and the ETESIAN Phase 1b study in adult participants with allergic asthma. In these communications, the company highlights measures such as the Urticaria Activity Score over 7 days (UAS7), hives and itch severity scores, airway hyperresponsiveness, sputum eosinophils and serum tryptase as key clinical and pharmacodynamic endpoints used to assess briquilimab’s activity and safety.

Clinical programs and study designs

In CSU, the BEACON study is described as a randomized, double-blind, placebo-controlled Phase 1b/2a trial evaluating multiple ascending doses of subcutaneous briquilimab in adult participants with moderate to severe disease despite treatment with high-dose antihistamines. Jasper identifies safety and tolerability as primary endpoints, with secondary endpoints focused on clinical activity and pharmacokinetics/pharmacodynamics, including measurement of serum tryptase and mast cells in skin. Jasper has also discussed an open-label extension study in chronic urticarias, enrolling CSU patients from BEACON and CIndU patients from the SPOTLIGHT study, with participants treated on a specified dosing schedule of briquilimab.

In asthma, Jasper has reported preliminary data from the ETESIAN Phase 1b/2a study, which it describes as a single-dose, double-blind, placebo-controlled allergen challenge study in adult participants with allergic asthma. The study uses a single 180 mg subcutaneous dose of briquilimab and evaluates endpoints such as early and late asthmatic responses, changes in airway hyperresponsiveness, mast cell depletion and recovery, sputum eosinophils, and safety. Company communications indicate that briquilimab was well tolerated in this study, with no dose-limiting toxicities observed and safety observations potentially related to KIT blockade described as infrequent and generally low grade.

Regulatory status and capital markets

Jasper Therapeutics’ voting common stock trades on The Nasdaq Stock Market LLC under the symbol JSPR, and its redeemable warrants trade under the symbol JSPRW, as disclosed in multiple Form 8-K filings. The company has used the public equity markets to fund its clinical development programs. For example, Jasper reported an underwritten public offering of common stock, pre-funded warrants and common warrants, with gross proceeds expected to be approximately $30 million before expenses, and stated that it intends to use the net proceeds to advance preclinical and clinical development of briquilimab in mast cell driven diseases and for general corporate purposes.

In addition to financing activities, Jasper has reported corporate actions such as a workforce reduction and reorganization to extend its cash runway, along with a decision to halt non–mast cell focused clinical and preclinical programs, including certain investigator-sponsored trials and a SCID clinical program. The company has stated that this reorganization is intended to concentrate resources on briquilimab development in mast cell driven diseases such as CSU and CIndU.

Governance and shareholder matters

Jasper files periodic and current reports with the U.S. Securities and Exchange Commission. In a Form 8-K describing its annual meeting of stockholders, the company reported on the election of Class I directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation and the frequency of such votes. These disclosures provide insight into Jasper’s corporate governance practices and shareholder engagement.

Key themes for investors

Based on Jasper’s public statements, several themes characterize the company’s profile:

• Single lead program focus: Jasper repeatedly describes its focus on developing briquilimab as a therapeutic for chronic mast cell diseases, with clinical studies in CSU, CIndU and asthma.
• Mechanism-driven approach: The company emphasizes briquilimab’s mechanism of blocking stem cell factor binding to KIT, leading to mast cell depletion via apoptosis and removal of a source of inflammatory responses in mast cell driven diseases.
• Clinical-stage risk profile: As a clinical-stage biotechnology company, Jasper’s disclosures highlight ongoing and planned studies, safety and efficacy observations, and the need for continued capital to support development programs.
• Nasdaq listing: Jasper’s common stock and warrants are listed on Nasdaq, providing public market access and regulatory reporting obligations under U.S. securities laws.

FAQs about Jasper Therapeutics, Inc. (JSPR)

• What does Jasper Therapeutics, Inc. do?
  Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that states it is focused on developing briquilimab, a targeted aglycosylated monoclonal antibody, as a therapeutic for chronic mast cell diseases such as chronic urticaria and asthma. The company is conducting clinical studies of briquilimab in patients with chronic spontaneous urticaria, chronic inducible urticaria and asthma.
• How does briquilimab work according to Jasper?
  Jasper describes briquilimab as an antibody that blocks stem cell factor from binding to the cell-surface receptor KIT (CD117). This inhibition disrupts a critical survival signal, leading to depletion of mast cells via apoptosis and removing an underlying source of the inflammatory response in mast cell driven diseases.
• What clinical indications is Jasper studying?
  According to Jasper’s press releases, the company is conducting clinical studies of briquilimab in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, including allergic asthma.
• What stage of development is Jasper in?
  Jasper describes itself as a clinical-stage biotechnology company. Its lead product candidate, briquilimab, is being evaluated in Phase 1b/2a studies in CSU and asthma and in related open-label extension studies in chronic urticarias, rather than being commercially marketed.
• On which exchange does JSPR trade?
  Form 8-K filings state that Jasper Therapeutics’ voting common stock is listed on The Nasdaq Stock Market LLC under the trading symbol JSPR. Redeemable warrants are listed on Nasdaq under the symbol JSPRW.
• What is the focus of Jasper’s BEACON study?
  The BEACON study is described by Jasper as a randomized, double-blind, placebo-controlled Phase 1b/2a trial of subcutaneous briquilimab in adult participants with moderate to severe chronic spontaneous urticaria despite high-dose antihistamines. The primary endpoints are safety and tolerability, with secondary endpoints assessing clinical activity and pharmacokinetics/pharmacodynamics.
• What is the ETESIAN study?
  Jasper reports that the ETESIAN Phase 1b/2a study is a single-dose, double-blind, placebo-controlled allergen challenge study in adult participants with allergic asthma. It evaluates a single 180 mg subcutaneous dose of briquilimab, with key assessments including early and late asthmatic responses, airway hyperresponsiveness, mast cell depletion and recovery, sputum eosinophils and safety.
• How is Jasper funding its clinical programs?
  According to a Form 8-K and related press release, Jasper entered into an underwriting agreement for a public offering of common stock, pre-funded warrants and common warrants, with gross proceeds expected to be approximately $30 million before expenses. The company states that it intends to use the net proceeds to advance briquilimab development in mast cell driven diseases and for general corporate purposes.
• Has Jasper made any recent corporate restructuring decisions?
  In a Form 8-K, Jasper disclosed that its board approved a corporate reorganization that includes a workforce reduction of approximately 50% and a refined operating plan focusing on briquilimab clinical development in chronic urticaria, while halting other clinical and preclinical programs.
• Where is Jasper Therapeutics located?
  SEC filings list Jasper Therapeutics, Inc. in Redwood City, California, in connection with its corporate address and telephone number.